News | Cath Lab | May 15, 2017

Race, Gender and Socioeconomic Factors Impact PCI Outcomes

Study finds women and minorities have greater risk of recurrent cardiac events within first year after PCI compared to Caucasian men

Race, Gender and Socioeconomic Factors Impact PCI Outcomes, PLATINUM Diversity study, SCAI 2017

May 15, 2017 — A first-of-its-kind study discovered that women and minorities who underwent a percutaneous coronary intervention (PCI) are at greater risk of experiencing recurrent cardiac events within the first year after their procedure compared to Caucasian men. Those outcomes may be attributable to their race, gender and socioeconomic status rather than the PCI procedure itself. Results from “Interaction Effects of Race/Ethnicity and Sex on Outcomes after PCI: A Subanalysis of the PLATINUM Diversity study” were presented as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2017 Scientific Sessions May 10-13 in New Orleans.

The trial is the first prospective study that enrolled solely women and minorities, a group that historically has been under-represented in cardiovascular clinical trials. The purpose of the PLATINUM Diversity trial was to come up with a novel way to enroll enough women and minorities to compare outcomes among different genders and race where results would be statistically valid.

Wayne Batchelor, M.D., MHS, FSCAI, an interventional cardiologist at Southern Medical Group in Tallahassee, Fla., along with Roxana Mehran, M.D., from Mount Sinai Hospital in New York, served as the study’s co-principal investigator. Batchelor said the impetus for PLATINUM Diversity stemmed in part from past studies that showed a higher rate of stent thrombosis in African Americans, but noted there were severe limitations of those studies.

“We wanted to design a study to prospectively examine outcomes across a large sample of women and minorities and compare that with the same stent used in recent studies of large numbers of Caucasian men,” said Batchelor. “What is unique about our study is that, counter to prevailing assumptions, it shows that you can rapidly enroll women and minorities into a prospective registry and collect statistically valid data.”

PLATINUM Diversity enrolled U.S. patients who received one Promus Premier stent and self-identified as being female, black (of African heritage), Hispanic/Latino or American Indian/Alaskan Native. To enrich the study with women and minorities and allow for comparisons to white men, PLATINUM Diversity (N=1,501) patients were pooled with the Promus-Element Plus Post Approval Study (PE PAS) patients (N=2,687) for a total study sample of 4,188 patients.

Within this large cohort, there were 1,417 white and 427 minority women, and 1,635 white and 632 minority men available for analysis. The subgroup analysis evaluated one-year outcomes in both minority and white men and women and the inter-related effects of sex and race.

“What we found was that there were significant differences in adjusted outcomes between these groups, with especially higher risks of cardiac events in minority women at one year,” Batchelor continued. “However, these incremental risks appeared to be related to progression of the patient’s ischemic heart disease more than failure of the stent due to stent thrombosis or restenosis.”

For more information: www.scaiscientificsessions.org

Related Content

Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Overlay Init